Patent 10131667 was granted and assigned to Incyte on November, 2018 by the United States Patent and Trademark Office.
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.